1,348 results match your criteria Hematological Oncology[Journal]


Low-Dose Fludarabine and Cyclophosphamide Combined With Standard Dose Rituximab (LD-FCR) Is an Effective and Safe Regimen for Elderly Untreated Patients with Chronic Lymphocytic Leukemia: The Israeli CLL Study Group Experience.

Hematol Oncol 2019 Feb 12. Epub 2019 Feb 12.

Department of Hematology, Hadassah University Hospital and Hebrew University Medical School, Jerusalem, Israel.

Chronic lymphocytic leukemia (CLL) is a disease of elderly patients. The fludarabine, cyclophosphamide and rituximab (FCR) regimen is considered the treatment of choice for young fit patients with CLL, however, this combination is toxic for older patients. At the time this study was first planned and initiated, there was no standard chemo-immunotherapy regimen regarded as standard therapy for the less fit elderly patient with CLL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2580DOI Listing
February 2019
2 Reads

Treatment of diffuse large B-cell lymphoma with and without anthracyclines and rituximab in patients older than 60 years: 10-year results at a Latin American center.

Hematol Oncol 2019 Feb 11. Epub 2019 Feb 11.

Department of Hematology, Internal Medicine Division, Dr. José E. González University Hospital of the School of Medicine of the Universidad Autónoma de Nuevo León, Monterrey, México.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2579DOI Listing
February 2019
1 Read

Exercise prescription and tailored physical activity intervention in onco-hematology inpatients, a personalised bedside approach to improve clinical best-practice.

Hematol Oncol 2019 Feb 8. Epub 2019 Feb 8.

Sport and Exercise Medicine Division, Department of Medicine, University of Padova, IT.

Therapy of hematological malignancies lasts for long periods implicating various complications. The chemotherapy induces fatigue and forces bed rest. These features strongly contribute to a general impairment of the physical efficiency. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2576
Publisher Site
http://dx.doi.org/10.1002/hon.2576DOI Listing
February 2019
4 Reads

Differential expression of estrogen receptor-α on follicular dendritic cells from patients with grade 1-2 and grade 3 follicular lymphoma.

Hematol Oncol 2019 Feb 8. Epub 2019 Feb 8.

Department of Pathological Diagnostics, Yamagata University Faculty of Medicine, Yamagata, Japan.

Hormone therapy has been used for patients with estrogen receptor alpha (ERα)-positive breast cancers. Recently, some studies reported the expression of ERα on neoplastic cells from B cell lymphomas. However, there has been only one report of ERα expression on the follicular dendritic cells (FDCs) that structurally and functionally support the microenvironment of follicular lymphomas (FLs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2577DOI Listing
February 2019
1 Read

FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma.

Hematol Oncol 2019 Feb 8. Epub 2019 Feb 8.

Sackler Faculty of Medicine Tel-Aviv University, Tel-Aviv, Israel.

We evaluated the role of 18-Fluoro-2-deoxy-D-glucose positron emission tomography ( FDG-PET) with computed tomography (CT) (PET/CT) as a diagnostic and prognostic tool in newly diagnosed marginal zone lymphoma (MZL) patients. This is a retrospective cohort study of patients with newly diagnosed MZL, treated with immunotherapy, chemotherapy regimens, surgery or helicobacter pylori eradication between 2008 and 2016 in a single tertiary center. Only patients who had a pre-treatment PET/CT (P-PET/CT) were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2578DOI Listing
February 2019

Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.

Hematol Oncol 2019 Feb 6. Epub 2019 Feb 6.

Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Chronic hepatitis C virus (HCV) infection is related with an increased risk of non-Hodgkin lymphomas (NHL). In indolent subtypes, regression of NHL was reported after HCV eradication with antiviral therapy (AT). In 2008 in Lombardy, a region of Northern Italy, the "Rete Ematologica Lombarda" (REL, Hematology Network of Lombardy-Lymphoma Workgroup) started a prospective multicenter observational cohort study on NHL associated with HCV infection, named "Registro Lombardo dei Linfomi HCV-positivi" ("Lombardy Registry of HCV-associated non-Hodgkin lymphomas"). Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2575
Publisher Site
http://dx.doi.org/10.1002/hon.2575DOI Listing
February 2019
6 Reads

A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies.

Hematol Oncol 2019 Jan 13. Epub 2019 Jan 13.

Institute of Hematology "L. e A. Seràgnoli,", University of Bologna, Bologna, Italy.

Existing therapies for Sézary syndrome (SS) are limited in efficacy and in disease control, and patients have very poor prognosis. Here, we report a case report of a patient who has a 16-year history of SS and related treatments (both standard and experimental). In particular, two drugs, one conventional (gemcitabine) and one experimental (mogamulizumab), were able to induce long lasting response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2573DOI Listing
January 2019

Treatment of diffuse large B-cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP-16).

Hematol Oncol 2018 Dec 27. Epub 2018 Dec 27.

Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2572
Publisher Site
http://dx.doi.org/10.1002/hon.2572DOI Listing
December 2018
10 Reads

Exportin-1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma.

Hematol Oncol 2018 Dec 13. Epub 2018 Dec 13.

Centro de Investigación del Cáncer de Salamanca; Servicio de Hematología, Hospital Universitario de Salamanca; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2570
Publisher Site
http://dx.doi.org/10.1002/hon.2570DOI Listing
December 2018
10 Reads

Cutaneous manifestations of hematologic malignancies the experience of an Italian dermatology department.

Hematol Oncol 2018 Nov 28. Epub 2018 Nov 28.

Di.S.Sal. Section of Dermatology, University of Genoa, San Martino Polyclinic Hospital, Genoa, Italy.

In recent years, dermatologic manifestations in oncohematologic patients have become more common. The aim of our study was to determine the incidence and heterogeneity of skin manifestations in patients followed at our Hematology Department. This observational monocentrical study was conducted on 60 patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2569DOI Listing
November 2018
11 Reads

The acceleration of CAR-T therapy in non-Hodgkin lymphoma.

Hematol Oncol 2018 Nov 14. Epub 2018 Nov 14.

Seattle Cancer Care Alliance, University of Washington/Fred Hutchinson Cancer Research Center Seattle, Seattle, Washington, USA.

Recent advances in diffuse large B-cell lymphomas have included both identification of high-risk subtypes characterized by multiply relapsed and/or refractory disease as well as novel treatment in the form of cellular therapy. Chimeric antigen receptor (CAR)-T cell therapy is a recently developed approach to address the poor outcomes in this patient population. The CAR-T cell construct has evolved although several iterations as it transitioned from the lab to the clinic. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2568
Publisher Site
http://dx.doi.org/10.1002/hon.2568DOI Listing
November 2018
14 Reads

MicroRNA expression profiles discriminate childhood T- from B-acute lymphoblastic leukemia.

Hematol Oncol 2019 Feb 27;37(1):103-112. Epub 2018 Nov 27.

Laboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Recife, Brazil.

MicroRNAs (miRNAs) play a critical role on biological and cellular processes; the search for functional markers may be of importance for differential diagnosis, prognosis, and development of new therapeutic regimens. In this context, we evaluated the bone marrow miRNA profile of Brazilian children exhibiting T- or B-cell acute lymphoblastic leukemia (T-ALL or B-ALL), using massive parallel sequencing, using the HiSeq 2500 platform (Illumina). The differential expression analysis was conducted considering a leave-one-out approach and FDR ≤ 0. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2567
Publisher Site
http://dx.doi.org/10.1002/hon.2567DOI Listing
February 2019
8 Reads

Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis.

Hematol Oncol 2019 Feb 19;37(1):85-95. Epub 2018 Nov 19.

Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan.

To reduce post-transplant relapse, acute myeloid leukemia (AML) type remission induction chemotherapy has been attempted to reduce disease burden before allogeneic hematopoietic cell transplantation (HCT) in patients with advanced myelodysplastic syndrome (MDS). However, the efficacy of induction chemotherapy before HCT is unclear. We retrospectively analyzed the Japanese registration data of 605 adult patients, who had received allogeneic HCT for advanced MDS between 2001 and 2016, to compare the post-transplant relapse between patients who received induction chemotherapy followed by allogeneic HCT and those who received upfront HCT. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2566
Publisher Site
http://dx.doi.org/10.1002/hon.2566DOI Listing
February 2019
4 Reads

Managing the cervical spine in multiple myeloma patients.

Hematol Oncol 2018 Oct 17. Epub 2018 Oct 17.

Myeloma Spine Service, Department of Spinal Surgery, Royal National Orthopaedic Hospital, Stanmore, Middlesex, UK.

Discuss the relevant literature on surgical and nonsurgical treatments for multiple myeloma (MM) and their complementary effects on overall treatment. Existing surgical algorithms designed for neoplasia of the spine may not suit the management of spinal myeloma. Less than a fifth of metastatic, including myelomatous lesions, occur in the cervical spine but have a poorer prognosis and surgery in this area carries a higher morbidity. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2564
Publisher Site
http://dx.doi.org/10.1002/hon.2564DOI Listing
October 2018
11 Reads

Prognostic role of baseline F-FDG PET/CT parameters in MALT lymphoma.

Hematol Oncol 2019 Feb 8;37(1):39-46. Epub 2018 Nov 8.

Department of Nuclear Medicine, University of Brescia and Spedali Civili di Brescia, Brescia, Italy.

Mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent lymphoma with good prognosis and variable fluorine-18 fluorodeoxyglucose ( F-FDG) avidity. Many possible prognostic factors have been investigated with controversial results, but the possible prognostic role of F-FDG positron emission tomography/computed tomography (PET/CT) remains unclear. Our aim was to evaluate the prognostic impact of qualitative and semiquantitative baseline PET/CT parameters on outcome of MALT lymphoma. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2563
Publisher Site
http://dx.doi.org/10.1002/hon.2563DOI Listing
February 2019
17 Reads

Lymphomagenic properties of a HIV p17 variant derived from a splenic marginal zone lymphoma occurred in a HIV-infected patient.

Hematol Oncol 2018 Sep 27. Epub 2018 Sep 27.

Immunopathology and Biomarker Unit, Department of Translational Research, Centro di Riferimento Oncologico di Aviano, IRCCS, Aviano, Italy.

Despite antiretroviral therapy, HIV+ individuals still have increased risk to develop lymphomas, including marginal zone lymphomas, suggesting that factors other than HIV-related immunosuppression are probably acting as lymphomagenic factors in the HIV setting. The possible pathogenic involvement of HIV p17 protein variants was investigated in a particularly informative case of HIV-related splenic marginal zone lymphoma, which was negative for oncogenic virus infections, thus allowing us to assess the possible direct contribution of these HIV-encoded proteins to lymphomagenesis. The presence of p17 protein was analyzed by immunohistochemistry in lymphoma tissue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2562DOI Listing
September 2018
1 Read

The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis.

Hematol Oncol 2019 Feb 8;37(1):27-34. Epub 2018 Oct 8.

Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.

Randomized trials of maintenance therapy (MT) in diffuse large B cell lymphoma (DLBCL) are inconclusive regarding its effect on overall survival (OS) and disease control. We aimed to examine the efficacy and safety of MT in this meta-analysis. Systematic review and meta-analysis of randomized controlled trials comparing MT with observation or placebo, in patients with DLBCL, who achieved complete response (CR) or partial response (PR) after first-line chemotherapy with or without rituximab. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2561
Publisher Site
http://dx.doi.org/10.1002/hon.2561DOI Listing
February 2019
14 Reads

Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.

Hematol Oncol 2019 Feb 23;37(1):35-38. Epub 2018 Oct 23.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate that is highly effective in patients with relapsed/refractory anaplastic large cell lymphoma (ALCL). However, survival outcomes following suboptimal response or subsequent relapse are not well known. We conducted a multicenter study analyzing outcomes of patients with relapsed/refractory ALCL who have received BV with a secondary focus on survival after progression following BV. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2560
Publisher Site
http://dx.doi.org/10.1002/hon.2560DOI Listing
February 2019
11 Reads

Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.

Hematol Oncol 2018 Sep 7. Epub 2018 Sep 7.

Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.

The finding of an IgM monoclonal gammopathy often represents a diagnostic challenge. In fact, there are many pathological disorders associated with this condition, each of which has distinctive characteristics and requires specific clinical, instrumental, and laboratory assessments to set the appropriate treatment. This review has two aims. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2539DOI Listing
September 2018
7 Reads

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.

Hematol Oncol 2019 Feb 5;37(1):3-14. Epub 2018 Sep 5.

Institute of Hematology Lorenzo e Ariosto Seràgnoli, University of Bologna, Bologna, Italy.

The introduction of new therapeutic agents in chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), including the new kinase inhibitor idelalisib, has changed the therapeutic landscape of these diseases. However, the use of idelalisib is associated with a peculiar profile of side effects, which require an optimization of the current approach to prophylaxis and supportive treatment. Moving from the recognition that the abovementioned issue represents an unmet need in CLL and FL, a multidisciplinary panel of experts was convened to produce a consensus document aiming to provide practical recommendations for the management of the side effects during idelalisib therapy for CLL and FL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2540DOI Listing
February 2019
3 Reads

Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.

Hematol Oncol 2018 Dec 19;36(5):792-800. Epub 2018 Sep 19.

Department of Hematology/Oncology, Higashi Nagoya National Hospital, Nagoya, Japan.

The international staging system (ISS) is the most commonly used risk-stratification system for patients with multiple myeloma (MM) and is determined by serum albumin and β2-microglobulin levels. In the two determinants, β2-microglobulin levels are frequently observed to be elevated in patients with myeloma, particularly in those with renal impairment. In comparison with patients with intact immunoglobulin myeloma, patients with LC myeloma do not necessarily show decreased levels of serum albumin. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2559
Publisher Site
http://dx.doi.org/10.1002/hon.2559DOI Listing
December 2018
12 Reads

The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation.

Hematol Oncol 2019 Feb 28;37(1):54-61. Epub 2018 Sep 28.

Department of Hematology, Imamura General Hospital, Kagoshima, Japan.

Treatment options for patients with adult T cell leukemia/lymphoma (ATLL) who have relapsed disease after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are limited. To clarify which patients with ATLL are likely to benefit from these treatment options and to define patient populations for novel treatments, we performed a nationwide retrospective analysis of 252 Japanese patients who had relapsed ATLL after allo-HSCT. Some long-term survivors remained after tapering and withdrawal of immunosuppressive agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2558DOI Listing
February 2019
1 Read

Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.

Hematol Oncol 2019 Feb 5;37(1):96-102. Epub 2018 Dec 5.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Trabectedin is an FDA-approved DNA minor groove binder that has activity against translocation-associated sarcomas. Lurbinectedin is a next-generation minor groove binder with preclinical activity against myeloid leukemia cells. A dose-finding phase 1 clinical trial was performed in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with further assessment of safety and tolerability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2557DOI Listing
February 2019
9 Reads

Treatment of mucosa associated lymphoid tissue lymphoma with a long-term once-weekly regimen of oral azithromycin: Results from the phase II MALT-A trial.

Hematol Oncol 2019 Feb 19;37(1):22-26. Epub 2018 Sep 19.

Department of Medicine 1, Division of Oncology, Medical University of Vienna, Vienna, Austria.

The macrolide clarithromycin has been reported as active for therapy of mucosa associated lymphoid tissue (MALT) lymphoma. Pharmacokinetic properties, however, require continuous daily intake over a prolonged period of time. As the macrolide azithromycin is characterized by a long half-life as well as potential antineoplastic activity in vitro, we have performed a phase II trial of long-term once-weekly oral azithromycin for treatment of MALT lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2555DOI Listing
February 2019
4 Reads

Renewed interest for low-dose radiation therapy in follicular lymphomas: From biology to clinical applications.

Hematol Oncol 2018 Dec 26;36(5):723-732. Epub 2018 Aug 26.

Radiation Oncology Unit, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.

Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoproliferative disorders. Treatment strategies for FL may include several therapeutic choices, ranging from a "watchful waiting" approach to stem cell transplantation, mostly depending on staging, age, risk factors, and disease burden at diagnosis. The high radiosensitivity of FL compared with other solid tumors has been known since the beginning of radiotherapy treatment in lymphoma patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2538DOI Listing
December 2018
7 Reads

Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma.

Hematol Oncol 2018 Oct 26;36(4):709-712. Epub 2018 Aug 26.

Departamento de Oncologia Clínica e Experimental, Universidade Federal de São Paulo, UNIFESP, São Paulo, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2542DOI Listing
October 2018
1 Read

Circulating exosomal long noncoding RNA PRINS-First findings in monoclonal gammopathies.

Hematol Oncol 2018 Dec 13;36(5):786-791. Epub 2018 Sep 13.

Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Multiple myeloma is the second most common hematological malignancy characterized by focal lesions of malignant plasma cells in the bone marrow. These lesions contain subclones that directly influence survival of patients. Bone marrow biopsies are single-site biopsies and thus cannot contain all information about the tumor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2554DOI Listing
December 2018
4 Reads

Immunochemotherapeutic increase of peripheral absolute monocyte count predicts interstitial pneumonia in lymphoma patients.

Hematol Oncol 2018 Dec 19;36(5):779-785. Epub 2018 Sep 19.

National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Sino-US Center for Lymphoma and Leukemia, Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Interstitial pneumonia (IP) is one of the potentially fatal adverse events for lymphoma patients undergoing immunochemotherapy. However, the risk factors and predictive markers remain unclear for this complication. This retrospective study aims to explore whether the change of absolute monocyte count (AMC) during immunochemotherapy is correlated with IP occurrence and progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2556DOI Listing
December 2018

Long-term results of the risk-stratified treatment of childhood acute lymphoblastic leukemia in China.

Hematol Oncol 2018 Oct 22;36(4):679-688. Epub 2018 Aug 22.

Department of Hematology/Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Key Lab of Pediatric Hematology & Oncology of China Ministry of Health, Shanghai, China.

Long-term follow-up data for childhood acute lymphoblastic leukemia (ALL) are scarce in China because of lacking population-based and hospitalized registry system. This retrospective study, conducted at Shanghai's Children's Medical Center in China (SCMC), aimed to investigate the long-term results of childhood ALL and to identify prognostic factors. The Pediatric Oncology Network Database, designed by St. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2541DOI Listing
October 2018
28 Reads

The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.

Hematol Oncol 2018 Oct 7;36(4):693-700. Epub 2018 Sep 7.

Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", Athens, Greece.

The demethylating factor 5-azacytidine (5-AZA) improves survival in intermediate-2 and high-risk myelodysplastic syndrome (MDS) patients [according to the International Prognostic Score System (IPSS)] responding to treatment. However, the outcome of patients achieving stable disease (SD) is unclear. This retrospective study of the Hellenic MDS Study Group included 353 intermediate-2 or high IPSS risk patients treated with 5-AZA. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2551
Publisher Site
http://dx.doi.org/10.1002/hon.2551DOI Listing
October 2018
5 Reads

Frontline treatment for transplant-eligible multiple myeloma: A 6474 patients network meta-analysis.

Hematol Oncol 2019 Feb 20;37(1):62-74. Epub 2018 Sep 20.

Post-graduation Program in Epidemiology-Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Autologous transplantation continues to be the cornerstone of younger and fit multiple myeloma patients. It is known that frontline induction therapy before transplantation can influence post-transplant results. Therefore, best frontline treatment for transplant-eligible patients should be based on best available evidence to guide therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2552DOI Listing
February 2019
3 Reads

Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.

Hematol Oncol 2018 Dec 13;36(5):773-778. Epub 2018 Sep 13.

First Medical Department, Charles University General Hospital in Prague, Czech Republic.

Rituximab maintenance (RM) prolongs survival of elderly patients with mantle cell lymphoma (MCL). Persistent minimal residual disease (MRD) after induction repeatedly correlated with shorter progression-free survival (PFS). However, none of the published studies analyzed patients treated with RM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2550DOI Listing
December 2018
5 Reads

Monoclonal gammopathy of undetermined significance in Chinese population: A prospective epidemiological study.

Hematol Oncol 2019 Feb 1;37(1):75-79. Epub 2018 Oct 1.

Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.

The aim of this study was to identify the prevalence of monoclonal gammopathy of undetermined significance (MGUS) in different groups of age and the clinical features in China. This multicenter prospective study enrolled 1797 health subjects. The overall prevalence of MGUS was 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2548DOI Listing
February 2019
14 Reads
3.084 Impact Factor

Extranodal lymphomas in the public health system in Chile: Analysis of 1251 patients from the National Adult Cancer Program.

Hematol Oncol 2019 Feb 14;37(1):47-53. Epub 2018 Sep 14.

Medicine Service, Hematology Section, Hospital del Salvador, University of Chile, Santiago, Chile.

The aim of the study was to describe the clinical and epidemiological characteristics, anatomic and histologic distribution, and treatment results of extranodal lymphomas (ENLs), diagnosed and treated in the public health system in Chile. We included patients with ENL diagnosed from 1998 to 2014, in 17 cancer centers, registered prospectively in the database of the National Adult Cancer Program (PANDA) of the Ministry of Health. Treatment was based on the local protocols for each lymphoma subtype. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2547
Publisher Site
http://dx.doi.org/10.1002/hon.2547DOI Listing
February 2019
13 Reads

Outcome of allogeneic hematopoietic cell transplantation in patients with adult T-cell leukemia.

Hematol Oncol 2018 Oct 10;36(4):651-655. Epub 2018 Sep 10.

Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Adult T-cell leukemia/lymphoma (ATL) is an aggressive peripheral T-cell neoplasm, and the outcome of patients with ATL after chemotherapy is poor. Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is a curative treatment modality for ATL, and four factors, namely, age > 50 years, male recipient, lack of complete remission at transplantation, and transplantation of cord blood, were previously shown to be associated with poor survival. We retrospectively analyzed the outcome of 21 patients with ATL who had undergone allo-HSCT at our hospital during a 3-year period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2549DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221141PMC
October 2018
6 Reads

Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals.

Hematol Oncol 2018 Dec 16;36(5):757-764. Epub 2018 Aug 16.

Division of Infectious Diseases, Ospedale Regionale di Lugano, Lugano, Switzerland.

The prognostic factors and outcome of 58 acquired immunodeficiency syndrome-related diffuse large B-cell lymphoma (AR-DLBCL) patients from the Swiss HIV Cohort Study, diagnosed from 2004 to 2011, were compared with those of 326 immunocompetent (IC)-DLBCL from the Hematology Division of the Amedeo Avogadro University (Italy) and the Oncology Institute of Southern Switzerland. Median follow-up was 6 years; 5-year overall survival (OS) was 68% (95% CI: 63%-73%) in IC-DLBCL and 63% (95% CI: 49%-75%) in AR-DLBCL (P = .220). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2536DOI Listing
December 2018
6 Reads

Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.

Hematol Oncol 2018 Oct 11;36(4):671-678. Epub 2018 Sep 11.

Department of Medical Oncology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.

Consolidation in myeloma patients with high-dose melphalan chemotherapy (Mel HDCT) and autologous transplantation (ASCT) is standard of care since more than 2 decades. However, definite cure remains exceptional despite intensive treatment, and improving effectiveness of HDCT remains an unmet clinical need. Combining intensified bendamustine with melphalan may represent an option. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2546DOI Listing
October 2018
1 Read

Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases.

Hematol Oncol 2018 Dec 6;36(5):801-803. Epub 2018 Sep 6.

Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2545DOI Listing
December 2018
2 Reads
3.084 Impact Factor

Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia?

Hematol Oncol 2019 Feb 5;37(1):80-84. Epub 2018 Oct 5.

Hematology Department, Nancy University Hospital, Vandoeuvre les Nancy, France.

Obesity has been associated with an increased risk of developing acute myeloblastic leukaemia (AML). The outcome of AML patients could thus be dependent on their nutritional status that can be evaluated by the simple measurement of serum albumin (SA) and body mass index (BMI). These two parameters could have a value as prognostic factors to guide patients' management. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2543
Publisher Site
http://dx.doi.org/10.1002/hon.2543DOI Listing
February 2019
15 Reads

Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis.

Hematol Oncol 2018 Oct 11;36(4):701-708. Epub 2018 Sep 11.

Incyte Corporation, Wilmington, DE, USA.

Ruxolitinib is the first Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis, where its efficacy is often associated with cytopenia. It is possible that the severity of cytopenia is in part driven by C . A once-daily sustained-release (SR) formulation of ruxolitinib was therefore developed to decrease the C /C ratio relative to twice-daily immediate-release (IR) ruxolitinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2544DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221065PMC
October 2018
1 Read

Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms.

Hematol Oncol 2018 Dec 3;36(5):740-748. Epub 2018 Aug 3.

Research Center for Molecular Medicine of the Austrian Academy of Science, Vienna, Austria.

Following the 47th American Society of Hematology Meeting in 2005, the late John Goldman and Tariq Mughal commenced a conference, the 1st Post-ASH Workshop, which brought together clinicians and scientists, to accelerate the adoption of new therapies for patients with myeloproliferative neoplasms (MPNs). The concept began with recognition of the CML success story following imatinib therapy, the discovery of JAK2 , and the demonstration that BCR-ABL1-negative MPNs are driven by abnormal JAK2 activation. This review is based on the presentations and deliberations at the XIIth Post-ASH Workshop on BCR-ABL1 positive and negative MPNs that took place on December 12 to 13, 2017, in Atlanta, Georgia, immediately following the 59th American Society of Hematology Meeting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2537DOI Listing
December 2018
10 Reads

Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab.

Hematol Oncol 2018 Oct 3;36(4):713-714. Epub 2018 Aug 3.

Department of Oncology/Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2533DOI Listing
October 2018
3 Reads

Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.

Hematol Oncol 2018 Oct 3;36(4):689-692. Epub 2018 Aug 3.

Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.

Because of the rarity of the disease, randomized clinical trials for multicentric Castleman disease (MCD) remain a challenge and, as a consequence, there is no established standard of care. Siltuximab is a chimeric immunoglobulin G1κ monoclonal antibody against human IL-6 which was recently approved by FDA. Eligible patients in Italy were granted early access through a Named Patient Program (NPP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2532DOI Listing
October 2018
10 Reads

Carfilzomib-associated cardiovascular adverse events in a non-Caucasian cohort of patients with multiple myeloma: A real-world experience.

Hematol Oncol 2018 Oct 3;36(4):715-717. Epub 2018 Aug 3.

Division of Hematology and Oncology, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2535DOI Listing
October 2018

Long noncoding RNAs and their epigenetic function in hematological diseases.

Hematol Oncol 2019 Feb 27;37(1):15-21. Epub 2018 Jul 27.

Cancer Center, First Hospital of Jilin University, Changchun, Jilin, China.

Recent discoveries demonstrate the importance of long noncoding RNA (lncRNA) in the regulation of multiple major processes impacting development, differentiation, and metastasis of hematological diseases through epigenetic mechanisms. In contrast to genetic changes, epigenetic modification does not modify genes but is frequently reversible, thus providing opportunities for targeted treatment using specific inhibitors. In this review, we will summarize the function and epigenetic mechanism of lncRNA in malignant hematologic diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2534DOI Listing
February 2019
8 Reads
3.084 Impact Factor